Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study
Zhenxin Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Lars Bauer(UCB Pharma (Germany)), Enxiang Tao(Sun Yat-sen University), Jian Wang(Huashan Hospital), Yiming Liu(Central South University), Mahnaz Asgharnejad(UCB Pharma (United States)), Chun‐Feng Liu(Soochow University), Erwin Surmann(UCB Pharma (Germany)), Haibo Xue, Ming Shao(Guangzhou Medical University)
Cited by 24
Related Papers
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
|Neurology|2006|677
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
|American Journal of Ophthalmology|2006|551
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
|The Lancet Neurology|2009|370
Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis
|New England Journal of Medicine|2007|258